The role of CB1 in immune modulation by cannabinoids

Pharmacology and Therapeutics

Volumn 137, Issue 3, 2013, Pages 365-374

  Kaplan, Barbara L F ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Cannabinoids; CB1 receptor; Immune modulation; Keywords

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CE 178253; MESSENGER RNA; NESS 0327; PF 095453; RIMONABANT; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CANNABINOID;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL DIFFERENTIATION; CELL MATURATION; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MANTLE CELL LYMPHOMA; MICROGLIA; MOLECULAR WEIGHT; MORTALITY; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; NORADRENALIN RELEASE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCLEROSIS; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CANNABINOIDS; HIV INFECTIONS; HUMANS; IMMUNOMODULATION; RECEPTOR, CANNABINOID, CB1;

MLCS; MLOWN;

EID: 84874113211     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.12.004     Document Type: Review

References (143)

1. V. Abadji, J.M. Lucas-Lenard, C. Chin, and D.A. Kendall Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs J Neurochem 72 5 1999 2032 2038
2. D.I. Abrams, J.F. Hilton, R.J. Leiser, S.B. Shade, T.A. Elbeik, and F.T. Aweeka Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial Ann Intern Med 139 4 2003 258 266
3. M. Agudelo, C. Newton, R. Widen, T. Sherwood, L. Nong, and H. Friedman Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes J Neuroimmune Pharmacol 3 1 2008 35 42
4. A. Arevalo-Martin, J.M. Vela, E. Molina-Holgado, J. Borrell, and C. Guaza Therapeutic action of cannabinoids in a murine model of multiple sclerosis J Neurosci 23 7 2003 2511 2516
5. S. Basu, and B.N. Dittel Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease Immunol Res 51 1 2011 26 38
6. S. Basu, A. Ray, and B.N. Dittel Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses J Immunol 187 11 2011 5720 5732
7. C. Benito, J.P. Romero, R.M. Tolon, D. Clemente, F. Docagne, and C.J. Hillard Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis J Neurosci 27 9 2007 2396 2402
8. D.W. Bonhaus, L.K. Chang, J. Kwan, and G.R. Martin Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses J Pharmacol Exp Ther 287 3 1998 884 888
9. C. Borner, A. Bedini, V. Hollt, and J. Kraus Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes Mol Pharmacol 73 3 2008 1013 1019
10. C. Borner, V. Hollt, and J. Kraus Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription Neuroimmunomodulation 14 6 2007 281 286
11. C. Borner, V. Hollt, W. Sebald, and J. Kraus Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids J Leukoc Biol 81 1 2007 336 343
12. C. Borner, E. Martella, V. Hollt, and J. Kraus Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2′-deoxycytidine Neuroimmunomodulation 19 3 2012 180 186
13. C. Borner, M. Smida, V. Hollt, B. Schraven, and J. Kraus Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling J Biol Chem 284 51 2009 35450 35460
14. M. Bouaboula, C. Poinot-Chazel, B. Bourrie, X. Canat, B. Calandra, and M. Rinaldi-Carmona Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1 Biochem J 312 Pt 2 1995 637 641
15. J.W. Brooks, G. Pryce, T. Bisogno, S.I. Jaggar, D.J. Hankey, and P. Brown Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors Eur J Pharmacol 439 1-3 2002 83 92
16. J.P. Buchweitz, P.W. Karmaus, K.J. Williams, J.R. Harkema, and N.E. Kaminski Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol J Leukoc Biol 83 3 2008 785 796
17. N.E. Buckley The peripheral cannabinoid receptor knockout mice: an update Br J Pharmacol 153 2 2008 309 318
18. N.E. Buckley, K.L. McCoy, E. Mezey, T. Bonner, A. Zimmer, and C.C. Felder Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor Eur J Pharmacol 396 2-3 2000 141 149
19. G.A. Cabral, K.N. Harmon, and S.J. Carlisle Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation Adv Exp Med Biol 493 2001 207 214
20. B. Calandra, M. Portier, A. Kerneis, M. Delpech, C. Carillon, and G. Le Fur Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor Eur J Pharmacol 374 3 1999 445 455
21. L. Callen, E. Moreno, P. Barroso-Chinea, D. Moreno-Delgado, A. Cortes, and J. Mallol Cannabinoid receptors CB1 and CB2 form functional heteromers in the brain J Biol Chem 287 25 2012 20851 20865
22. A. Chakrabarti, E.S. Onaivi, and G. Chaudhuri Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein DNA Seq 5 6 1995 385 388
23. W. Chen, B.L. Kaplan, S.T. Pike, L.A. Topper, N.R. Lichorobiec, and S.O. Simmons Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120 J Leukoc Biol 92 5 2012 1093 1102
24. X.P. Chen, W. Yang, Y. Fan, J.S. Luo, K. Hong, and Z. Wang Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i) Br J Pharmacol 161 8 2010 1817 1834
25. Y.C. Chung, E. Bok, S.H. Huh, J.Y. Park, S.H. Yoon, and S.R. Kim Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation J Immunol 187 12 2011 6508 6517
26. D.R. Compton, M.D. Aceto, J. Lowe, and B.R. Martin In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity J Pharmacol Exp Ther 277 2 1996 586 594
27. R. Condie, A. Herring, W.S. Koh, M. Lee, and N.E. Kaminski Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2 J Biol Chem 271 22 1996 13175 13183
28. B. Costa, A.E. Trovato, M. Colleoni, G. Giagnoni, E. Zarini, and T. Croci Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve Pain 116 1-2 2005 52 61
29. T. Croci, M. Landi, A.M. Galzin, and P. Marini Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents Br J Pharmacol 140 1 2003 115 122
30. J.L. Croxford, G. Pryce, S.J. Jackson, C. Ledent, G. Giovannoni, and R.G. Pertwee Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis J Neuroimmunol 193 1-2 2008 120 129
31. Y. Daaka, H. Friedman, and T.W. Klein Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation J Pharmacol Exp Ther 276 2 1996 776 783
32. M.L. De Jesus, J. Salles, J.J. Meana, and L.F. Callado Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates Neuroscience 140 2 2006 635 643
33. E. de Lago, M. Moreno-Martet, A. Cabranes, J.A. Ramos, and J. Fernandez-Ruiz Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects Neuropharmacology 62 7 2012 2299 2308
34. J.M. Derocq, M. Segui, J. Marchand, G. Le Fur, and P. Casellas Cannabinoids enhance human B-cell growth at low nanomolar concentrations FEBS Lett 369 2-3 1995 177 182
35. V. Di Marzo, T. Bisogno, L. De Petrocellis, I. Brandi, R.G. Jefferson, and R.L. Winckler Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands Biochem Biophys Res Commun 281 2 2001 444 451
36. Y. Do, R.J. McKallip, M. Nagarkatti, and P.S. Nagarkatti Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation J Immunol 173 4 2004 2373 2382
37. C.C. Felder, K.E. Joyce, E.M. Briley, M. Glass, K.P. Mackie, and K.J. Fahey LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation J Pharmacol Exp Ther 284 1 1998 291 297
38. S. Galiegue, S. Mary, J. Marchand, D. Dussossoy, D. Carriere, and P. Carayon Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur J Biochem 232 1 1995 54 61
39. S.J. Gatley, A.N. Gifford, N.D. Volkow, R. Lan, and A. Makriyannis 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors Eur J Pharmacol 307 3 1996 331 338
40. C.M. Gerard, C. Mollereau, G. Vassart, and M. Parmentier Molecular cloning of a human cannabinoid receptor which is also expressed in testis Biochem J 279 Pt 1 1991 129 134
41. M. Glass, and C.C. Felder Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor J Neurosci 17 14 1997 5327 5333
42. A. Goutopoulos, P. Fan, A.D. Khanolkar, X.Q. Xie, S. Lin, and A. Makriyannis Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability Bioorg Med Chem 9 7 2001 1673 1684
43. A. Gross, A. Terraza, J. Marchant, M. Bouaboula, S. Ouahrani-Bettache, and J.P. Liautard A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis J Leukoc Biol 67 3 2000 335 344
44. K. Gustafsson, B. Sander, J. Bielawski, Y.A. Hannun, and J. Flygare Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism Mol Cancer Res 7 7 2009 1086 1098
45. K. Gustafsson, X. Wang, D. Severa, M. Eriksson, E. Kimby, and M. Merup Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation Int J Cancer 123 5 2008 1025 1033
46. K.H. Han, S. Lim, J. Ryu, C.W. Lee, Y. Kim, and J.H. Kang CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages Cardiovasc Res 84 3 2009 378 386
47. L. Hanus, S. Abu-Lafi, E. Fride, A. Breuer, Z. Vogel, and D.E. Shalev 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor Proc Natl Acad Sci U S A 98 7 2001 3662 3665
48. V.L. Hegde, M. Nagarkatti, and P.S. Nagarkatti Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties Eur J Immunol 40 12 2010 3358 3371
49. C.J. Hillard, S. Manna, M.J. Greenberg, R. DiCamelli, R.A. Ross, and L.A. Stevenson Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1) J Pharmacol Exp Ther 289 3 1999 1427 1433
50. A.C. Howlett, and R.M. Fleming Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes Mol Pharmacol 26 3 1984 532 538
51. A.C. Howlett, J.M. Qualy, and L.L. Khachatrian Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs Mol Pharmacol 29 3 1986 307 313
52. B.D. Hudson, T.E. Hebert, and M.E. Kelly Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors Br J Pharmacol 160 3 2010 627 642
53. T.C. Islam, A.C. Asplund, J.M. Lindvall, L. Nygren, J. Liden, and E. Kimby High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma Leukemia 17 9 2003 1880 1890
54. T.R. Jan, and N.E. Kaminski Role of mitogen-activated protein kinases in the differential regulation of interleukin-2 by cannabinol J Leukoc Biol 69 5 2001 841 849
55. T.R. Jan, G.K. Rao, and N.E. Kaminski Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity Mol Pharmacol 61 2 2002 446 454
56. Z. Jarai, J.A. Wagner, K. Varga, K.D. Lake, D.R. Compton, and B.R. Martin Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors Proc Natl Acad Sci U S A 96 24 1999 14136 14141
57. O. Jbilo, J.M. Derocq, M. Segui, G. Le Fur, and P. Casellas Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60 FEBS Lett 448 2-3 1999 273 277
58. W. Jin, S. Brown, J.P. Roche, C. Hsieh, J.P. Celver, and A. Kovoor Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization J Neurosci 19 10 1999 3773 3780
59. N.E. Kaminski, M.E. Abood, F.K. Kessler, B.R. Martin, and A.R. Schatz Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation Mol Pharmacol 42 5 1992 736 742
60. B.L. Kaplan, C.E. Rockwell, and N.E. Kaminski Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes J Pharmacol Exp Ther 306 3 2003 1077 1085
61. B.L. Kaplan, A.E. Springs, and N.E. Kaminski The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT) Biochem Pharmacol 76 6 2008 726 737
62. P.W. Karmaus, W. Chen, R.B. Crawford, J.R. Harkema, B.L. Kaplan, and N.E. Kaminski Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection J Leukoc Biol 90 5 2011 983 995
63. M. Karsak, E. Gaffal, R. Date, L. Wang-Eckhardt, J. Rehnelt, and S. Petrosino Attenuation of allergic contact dermatitis through the endocannabinoid system Science 316 5830 2007 1494 1497
64. C.S. Kearn, K. Blake-Palmer, E. Daniel, K. Mackie, and M. Glass Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67 5 2005 1697 1704
65. A.D. Khanolkar, V. Abadji, S. Lin, W.A. Hill, G. Taha, and K. Abouzid Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand J Med Chem 39 22 1996 4515 4519
66. T.W. Klein, C.A. Newton, N. Nakachi, and H. Friedman Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection J Immunol 164 12 2000 6461 6466
67. E. Kozela, N. Lev, N. Kaushansky, R. Eilam, N. Rimmerman, and R. Levy Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice Br J Pharmacol 163 7 2011 1507 1519
68. G. Kunos, D. Osei-Hyiaman, S. Batkai, K.A. Sharkey, and A. Makriyannis Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 30 1 2009 1 7
69. R. Lan, J. Gatley, Q. Lu, P. Fan, S.R. Fernando, and N.D. Volkow Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand AAPS PharmSci 1 2 1999 E4
70. R. Lan, Q. Liu, P. Fan, S. Lin, S.R. Fernando, and D. McCallion Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists J Med Chem 42 4 1999 769 776
71. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.F. Aubert, and F. Beslot Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 5400 1999 401 404
72. K. Li, J.Y. Feng, Y.Y. Li, B. Yuece, X.H. Lin, and L.Y. Yu Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice Pancreas 42 1 2012 123 129
73. S. Lin, A.D. Khanolkar, P. Fan, A. Goutopoulos, C. Qin, and D. Papahadjis Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability J Med Chem 41 27 1998 5353 5361
74. J. Liu, S. Batkai, P. Pacher, J. Harvey-White, J.A. Wagner, and B.F. Cravatt Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor J Biol Chem 278 45 2003 45034 45039
75. C. Lombard, V.L. Hegde, M. Nagarkatti, and P.S. Nagarkatti Perinatal exposure to Delta9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens J Pharmacol Exp Ther 339 2 2011 607 617
76. Z.Y. Lou, C. Chen, Q. He, C.B. Zhao, and B.G. Xiao Targeting CB(2) receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis Mol Immunol 49 3 2011 453 461
77. Z.Y. Lou, C.B. Zhao, and B.G. Xiao Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist J Neurosci Res 90 1 2012 84 95
78. T.S. Lu, H.K. Avraham, S. Seng, S.D. Tachado, H. Koziel, and A. Makriyannis Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells J Immunol 181 9 2008 6406 6416
79. T. Lu, C. Newton, I. Perkins, H. Friedman, and T.W. Klein Role of cannabinoid receptors in Delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila Eur J Pharmacol 532 1-2 2006 170 177
80. W.D. Lyman, J.R. Sonett, C.F. Brosnan, R. Elkin, and M.B. Bornstein Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis J Neuroimmunol 23 1 1989 73 81
81. K. Mackie, W.A. Devane, and B. Hille Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells Mol Pharmacol 44 3 1993 498 503
82. K. Mackie, and B. Hille Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells Proc Natl Acad Sci U S A 89 9 1992 3825 3829
83. K. Mackie, Y. Lai, R. Westenbroek, and R. Mitchell Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor J Neurosci 15 10 1995 6552 6561
84. K. Maresz, G. Pryce, E.D. Ponomarev, G. Marsicano, J.L. Croxford, and L.P. Shriver Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells Nat Med 13 4 2007 492 497
85. G. Marsicano, C.T. Wotjak, S.C. Azad, T. Bisogno, G. Rammes, and M.G. Cascio The endogenous cannabinoid system controls extinction of aversive memories Nature 418 6897 2002 530 534
86. I. Matias, P. Pochard, P. Orlando, M. Salzet, J. Pestel, and V. Di Marzo Presence and regulation of the endocannabinoid system in human dendritic cells Eur J Biochem 269 15 2002 3771 3778
87. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 6284 1990 561 564
88. E.A. McCaw, H. Hu, G.T. Gomez, A.L. Hebb, M.E. Kelly, and E.M. Denovan-Wright Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice Eur J Biochem 271 23-24 2004 4909 4920
89. R.J. McKallip, C. Lombard, B.R. Martin, M. Nagarkatti, and P.S. Nagarkatti Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo J Pharmacol Exp Ther 302 2 2002 451 465
90. P.J. McLaughlin Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity Behav Pharmacol 23 5-6 2012 537 550
91. S.J. Mnich, R.R. Hiebsch, R.M. Huff, and S. Muthian Anti-inflammatory properties of CB1-receptor antagonist involves beta2 adrenoceptors J Pharmacol Exp Ther 333 2 2010 445 453
92. B. Mukhopadhyay, J. Liu, D. Osei-Hyiaman, G. Godlewski, P. Mukhopadhyay, and L. Wang Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma J Biol Chem 285 25 2010 19002 19011
93. S. Munro, K.L. Thomas, and M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature (London) 365 1993 61 65
94. J.R. Muppidi, T.I. Arnon, Y. Bronevetsky, N. Veerapen, M. Tanaka, and G.S. Besra Cannabinoid receptor 2 positions and retains marginal zone B cells within the splenic marginal zone J Exp Med 208 10 2011 1941 1948
95. P. Nagarkatti, R. Pandey, S.A. Rieder, V.L. Hegde, and M. Nagarkatti Cannabinoids as novel anti-inflammatory drugs Future Med Chem 1 7 2009 1333 1349
96. Y. Nakano, S. Pross, and H. Friedman Contrasting effect of delta-9-tetrahydrocannabinol on IL-2 activity in spleen and lymph node cells of mice of different ages Life Sci 52 1 1993 41 51
97. C.A. Newton, P.J. Chou, I. Perkins, and T.W. Klein CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection J Neuroimmune Pharmacol 4 1 2009 92 102
98. J.L. Niehaus, Y. Liu, K.T. Wallis, M. Egertova, S.G. Bhartur, and S. Mukhopadhyay CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a Mol Pharmacol 72 6 2007 1557 1566
99. L. Nong, C. Newton, H. Friedman, and T.W. Klein CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types Adv Exp Med Biol 493 2001 229 233
100. W. Notcutt, R. Langford, P. Davies, S. Ratcliffe, and R. Potts A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols) Mult Scler 18 2 2012 219 228
101. R. Pandey, V.L. Hegde, M. Nagarkatti, and P.S. Nagarkatti Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model J Pharmacol Exp Ther 338 3 2011 819 828
102. S. Patel, and C.J. Hillard Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice J Pharmacol Exp Ther 297 2 2001 629 637
103. G. Patrini, P. Sacerdote, D. Fuzio, B. Manfredi, and D. Parolaro Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound J Neuroimmunol 80 1-2 1997 143 148
104. J.P. Pereira, J. An, Y. Xu, Y. Huang, and J.G. Cyster Cannabinoid receptor 2 mediates the retention of immature B cells in bone marrow sinusoids Nat Immunol 10 4 2009 403 411
105. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, and M.R. Elphick International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2) Pharmacol Rev 62 4 2010 588 631
106. D. Prentiss, R. Power, G. Balmas, G. Tzuang, and D.M. Israelski Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting J Acquir Immune Defic Syndr 35 1 2004 38 45
107. S.H. Pross, Y. Nakano, S. McHugh, R. Widen, T.W. Klein, and H. Friedman Contrasting effects of THC on adult murine lymph node and spleen cell populations stimulated with mitogen or anti-CD3 antibody Immunopharmacol Immunotoxicol 14 3 1992 675 687
108. S.H. Pross, Y. Nakano, R. Widen, S. McHugh, C.A. Newton, and T.W. Klein Differing effects of delta-9-tetrahydrocannabinol (THC) on murine spleen cell populations dependent upon stimulators Int J Immunopharmacol 14 6 1992 1019 1027
109. G. Pryce, Z. Ahmed, D.J. Hankey, S.J. Jackson, J.L. Croxford, and J.M. Pocock Cannabinoids inhibit neurodegeneration in models of multiple sclerosis Brain 126 Pt 10 2003 2191 2202
110. G. Pryce, and D. Baker Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors Br J Pharmacol 150 4 2007 519 525
111. E. Ramil, A.J. Sanchez, P. Gonzalez-Perez, A. Rodriguez-Antiguedad, N. Gomez-Lozano, and P. Ortiz The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain Mult Scler 16 2 2010 139 146
112. G.K. Rao, and N.E. Kaminski Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship J Pharmacol Exp Ther 317 2 2006 820 829
113. A. Ribeiro, V. Ferraz-de-Paula, M.L. Pinheiro, L.B. Vitoretti, D.P. Mariano-Souza, and W.M. Quinteiro-Filho Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor Eur J Pharmacol 678 1-3 2012 78 85
114. M. Rinaldi-Carmona, F. Barth, M. Heaulme, D. Shire, B. Calandra, and C. Congy SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett 350 1994 240 244
115. R.B. Rock, G. Gekker, S. Hu, W.S. Sheng, G.A. Cabral, and B.R. Martin WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors J Neuroimmune Pharmacol 2 2 2007 178 183
116. C.E. Rockwell, N.T. Snider, J.T. Thompson, J.P. Vanden Heuvel, and N.E. Kaminski Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2 Mol Pharmacol 70 1 2006 101 111
117. D.J. Rog, T.J. Nurmikko, T. Friede, and C.A. Young Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis Neurology 65 6 2005 812 819
118. S. Rossi, F. Buttari, V. Studer, C. Motta, P. Gravina, and M. Castelli The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis Mult Scler 17 3 2011 281 288
119. S. Rossi, R. Furlan, V.D. Chiara, L. Muzio, A. Musella, and C. Motta Cannabinoid CB1 receptors regulate neuronal TNF-alpha effects in experimental autoimmune encephalomyelitis Brain Behav Immun 25 6 2011 1242 1248
120. B. Rossi, E. Zenaro, S. Angiari, L. Ottoboni, S. Bach, and L. Piccio Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism J Neuroimmunol 233 1-2 2011 97 105
121. M.D. Roth, D.P. Tashkin, K.M. Whittaker, R. Choi, and G.C. Baldwin Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse Life Sci 77 14 2005 1711 1722
122. S. Ruiu, G.A. Pinna, G. Marchese, J.M. Mussinu, P. Saba, and S. Tambaro Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor J Pharmacol Exp Ther 306 1 2003 363 370
123. P. Sacerdote, P. Massi, A.E. Panerai, and D. Parolaro In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors J Neuroimmunol 109 2 2000 155 163
124. A.R. Schatz, W.S. Koh, and N.E. Kaminski â̂†9- tetrahydrocanabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function Immunopharmacology 26 1993 129 137
125. K.A. Seely, L.K. Brents, L.N. Franks, M. Rajasekaran, S.M. Zimmerman, and W.E. Fantegrossi AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies Neuropharmacology 63 5 2012 905 915
126. D. Shire, C. Carillon, M. Kaghad, B. Calandra, M. Rinaldi-Carmona, and G. Le Fur An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing J Biol Chem 270 8 1995 3726 3731
127. S.C. Shivers, C. Newton, H. Friedman, and T.W. Klein Delta 9-Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines Life Sci 54 17 1994 1281 1289
128. D. Sinha, T.I. Bonner, N.R. Bhat, and L.A. Matsuda Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies J Neuroimmunol 82 1 1998 13 21
129. S.R. Smith, G. Denhardt, and C. Terminelli The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models Eur J Pharmacol 432 1 2001 107 119
130. T.H. Smith, L.J. Sim-Selley, and D.E. Selley Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 160 3 2010 454 466
131. S.R. Smith, C. Terminelli, and G. Denhardt Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice J Pharmacol Exp Ther 293 1 2000 136 150
132. A.E. Springs, P.W. Karmaus, R.B. Crawford, B.L. Kaplan, and N.E. Kaminski Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol J Leukoc Biol 84 6 2008 1574 1584
133. M. Storr, D. Emmerdinger, J. Diegelmann, S. Pfennig, T. Ochsenkuhn, and B. Goke The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease PLoS One 5 2 2010 e9453
134. K. Sugamura, S. Sugiyama, T. Nozaki, Y. Matsuzawa, Y. Izumiya, and K. Miyata Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages Circulation 119 1 2009 28 36
135. G. Turu, P. Varnai, P. Gyombolai, L. Szidonya, L. Offertaler, and G. Bagdy Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors J Biol Chem 284 25 2009 16914 16921
136. P.W. Wacnik, K.M. Luhr, R.H. Hill, H.G. Ljunggren, K. Kristensson, and M. Svensson Cannabinoids affect dendritic cell (DC) potassium channel function and modulate DC T cell stimulatory capacity J Immunol 181 5 2008 3057 3066
137. J. Wager-Miller, R. Westenbroek, and K. Mackie Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example Chem Phys Lipids 121 1-2 2002 83 89
138. Y. Waksman, J.M. Olson, S.J. Carlisle, and G.A. Cabral The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells J Pharmacol Exp Ther 288 3 1999 1357 1366
139. B.S. Wong, M. Camilleri, I. Busciglio, P. Carlson, L.A. Szarka, and D. Burton Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome Gastroenterology 141 5 2011 1638 1647 (e1631-1637)
140. B.S. Wong, M. Camilleri, D. Eckert, P. Carlson, M. Ryks, and D. Burton Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea Neurogastroenterol Motil 24 4 2012 358-e169
141. M. Yuan, S.M. Kiertscher, Q. Cheng, R. Zoumalan, D.P. Tashkin, and M.D. Roth Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells J Neuroimmunol 133 1-2 2002 124 131
142. P.W. Zhang, H. Ishiguro, T. Ohtsuki, J. Hess, F. Carillo, and D. Walther Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse Mol Psychiatry 9 10 2004 916 931
143. A. Zimmer, A.M. Zimmer, A.G. Hohmann, M. Herkenham, and T.I. Bonner Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice Proc Natl Acad Sci U S A 96 10 1999 5780 5785